Evaluation of the Safety of Loargys Arginine Test System in Loargys-treated Patients

Part of paid clinical trials in Atlanta, Georgia.

Sponsor
Immedica Pharma US Inc
Study ID
NCT07573059
Status
Recruiting

Conditions

  • ARG1 Deficiency

Eligibility Criteria

Sex
ALL
Age
0 Years - 100 Years
Healthy Volunteers
Not accepted

Interventions

  • Loargys Arginine Test System — DEVICE
    Loargys Arginine Test System

Study Details

Arginase 1 deficiency (ARG1-D) is a rare condition in which the body cannot properly break down a substance called arginine. This leads to high levels of arginine and related substances in the blood, which can cause serious health problems and reduce quality of life. Loargys is a new treatment designed to lower arginine levels in people with ARG1-D. It works by providing a modified version of a natural enzyme that breaks down arginine in the blood. The dose of Loargys is adjusted for each patient based on their arginine levels. Because Loargys continues to break down arginine even after a blood sample has been taken, to ensure accurate results, a special substance (called nor-NOHA) is added to the blood collection tubes to stop this process after the sample is taken. The arginine levels are then measured using a standard laboratory test. The Loargys Arginine Test System used in this study includes both the special blood collection tubes and the laboratory test used to measure arginine. The purpose of this study is to evaluate the safety of this test system when used to measure arginine levels in patients receiving Loargys.

Key Dates

Start date
Apr 17, 2026
Status verified
May 2026
Primary completion
Jul 15, 2027
Completion
Jul 15, 2027

Study Design

Enrollment
100 participants (estimated)
Allocation
NA
Intervention model
SINGLE_GROUP
Primary purpose
OTHER

Arms

  • Other: Loargys Arginine Test System

Primary Outcome Measure

Incidence of AEs related to the Loargys Arginine Test System [ Time Frame: Through study completion, up to 21 months ]

Central Contacts

Locations (1)

FacilityCityStateZIPSite coordinators
Rare Disease ResearchAtlantaGeorgia303029
CLEAR Study Coordinator
678-883-6897

Find similar trials in Atlanta, GA